This patent essentially covers the induction of angiogenesis using the chemokine MCP-1. This patent would most likely synergize by combining administration of MCP-1 with hematopoietic stem cells and/or endothelial precursor cells.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.